Compare UBCP & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBCP | ACET |
|---|---|---|
| Founded | 1902 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 93.5M |
| IPO Year | N/A | N/A |
| Metric | UBCP | ACET |
|---|---|---|
| Price | $13.25 | $0.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 3.3K | ★ 1.8M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 6.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $30,516,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $10.24 | ★ N/A |
| Revenue Growth | ★ 4.40 | N/A |
| 52 Week Low | $12.25 | $0.45 |
| 52 Week High | $15.64 | $1.13 |
| Indicator | UBCP | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 35.71 |
| Support Level | $13.21 | $0.53 |
| Resistance Level | $13.40 | $0.70 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 100.00 | 17.45 |
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.